Sector News

Activist pressure spurs CEO switch at troubled Depomed

March 29, 2017
Life sciences

Depomed switched up its board last October to appease activist Starboard Value. But Starboard didn’t stop there, and the new wave of changes it’s spurred involves the drugmaker’s CEO.

Tuesday afternoon, the California company announced that Arthur Higgins, a 35-year pharma industry vet, had taken the chief exec reins—and a boardroom seat—from Jim Schoeneck, who had stepped down.

But that was far from the only tweak to Depomed’s director slate. The company also added former Barr Pharmaceuticals CFO William McKee and Starboard Value partner Gavin Molinelli to the mix, while bidding farewell to Samuel Saks and David Zenoff. James Fogarty, the one-time Lehman Brothers Holdings COO, will take over as chairman; he joined the group last October alongside Robert Savage, former worldwide chairman for Johnson & Johnson’s pharma group, and James Tyree, former EVP of pharma products at Abbott Laboratories.

Starboard—which has accused Depomed of “egregiously manipulating the corporate machinery to entrench management and the board”—was quick to tout the pharma experience of Higgins, who has served as both the CEO of Bayer Healthcare and the president of Abbott’s pharma division over his long industry tenure. “We are excited to have found such a qualified leader for the company,” Molinelli said in a statement, adding that the addition of McKee would “add valuable industry experience to the boardroom.”

While “a next move by Starboard did not come as a surprise” to industry-watchers, the timing of the management and board shakeup did, RBC Capital Markets analyst Randall Stanicky wrote in a Tuesday note to clients. While many had expected “potential action” after standstill restrictions from the October settlement expired earlier this month, “the move by Depomed ahead of time to announce a new CEO and chairman” and board overhaul “was not expected.”

The new governing group at Depmed will certainly have its work cut out for it, with the drugmaker also Tuesday pre-announcing a Q1 revenue miss—and its intent to revise its guidance in May. The company now expects its top-line tally to hit between $95 million and $100 million, falling below the $115 million analysts expected. The reasons? “Continued weakness” in opioid markets, wholesaler inventory scalebacks in Q1, and ongoing sales force issues that left “a significant number of openings” in the field last quarter.

While the changes could pave the way for a sale, to Stanicky, the “key questions from here” are whether there’s a “viable” buyer for the company out there—and what that buyer will pay. Depomed’s stock is down 21% so far for the year, he noted, and the company has already reportedly teamed up with Morgan Stanley to scout opportunities. “It is far from clear whether there is any interest in the asset,” he wrote, noting that “we are a long way” from the offers failed hostile suitor Horizon Pharma put forth back in 2015.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.